Acoustic wave platform nebuliser for inhaled delivery of biologic therapies

The ability of biologic medicines to specifically target the underlying mechanisms of a wide range of diseases has driven substantial interest and investment in their development.
This momentum facilitated the rapid development and approval of the first messenger RNA (mRNA)-based vaccines during the COVID-19 pandemic, highlighting the potential of novel therapeutic platforms and encouraging a more optimistic outlook for future drug development.
For On Drug Delivery, our CSO Elijah Nazarzedeh discusses how Nebu~flow offers opportunities for drug delivery to, and through the lung.
